Butyrate production

This result estimates your gut microbial community’s capacity to make butyrate from its DNA. It can describe a function shared by several groups of bacteria, but it doesn't establish how much butyrate they are making or whether a shortage explains your symptoms.

The measurement is exploratory. Research links reduced butyrate-producing capacity with several illnesses, but there is no validated target for preventing disease or extending life. A result can add context to a microbiome profile. Its value for choosing treatment remains unproven.

What This Result Captures

The test uses shotgun metagenomic sequencing of a stool sample. This reads microbial DNA across the community and estimates its genetic potential to produce butyrate. The result reflects the organisms and metabolic capabilities represented in that sample.

Genetic capacity and active production can differ. Bacteria need suitable food, and their activity depends on the conditions around them. A community can carry the necessary genes without producing the same amount of butyrate every day.

Chemical stool butyrate testing answers a different question: how much of the molecule remains in the collected stool. Most butyrate made in the colon is absorbed, so that concentration also depends on absorption and transit. Findings about fecal concentrations cannot be treated as direct measurements of this DNA-derived capacity.

How Gut Bacteria Make Butyrate

Many gut bacteria make butyrate by fermenting carbohydrates that reach the colon. These include certain fibers and resistant starch. Some production routes use other starting materials, including amino acids, so total capacity doesn't identify which foods supplied the fuel.

Faecalibacterium prausnitzii, Roseburia species and Eubacterium rectale are among the organisms involved. They often depend on products released by other bacteria. For example, Ruminococcus bromii can break down resistant starch into material other organisms can use. Several species can perform overlapping functions, which is why the absence of one named organism doesn't establish that the community has lost the ability to make butyrate.

Why the Colon Uses It

Butyrate is a major energy source for the cells lining the colon. Experiments in mice show that its use by these cells helps keep oxygen scarce inside the colon, supporting bacteria adapted to that environment. Experiments in cultured human intestinal cells also show that butyrate can strengthen the connections between cells.

These mechanisms help explain the interest in butyrate. They don't establish that a low stool DNA estimate means your lining is short of fuel, unusually permeable or inflamed. Those are separate biological questions.

Inflammatory Bowel Disease

Human research supports an association between inflammatory bowel disease and reduced microbial capacity for butyrate synthesis. One study measured a specific butyrate-production gene in stool using targeted PCR. Gene abundance was lower in both active and inactive Crohn’s disease, while the reduction in ulcerative colitis was found during active disease. This is related evidence from a narrower method than shotgun sequencing.

The pattern doesn't support a promise that capacity will return to a particular level during remission. Disease location, diet, inflammation and treatment can all differ between groups. Fecal calprotectin has an established role in assessing intestinal inflammation; butyrate-producing capacity hasn't been validated as a replacement for that assessment.

Metabolic Health and Fatigue

The metabolic evidence doesn't support treating all butyrate-producing bacteria as interchangeable. In a study of 353 adults, greater Coprococcus abundance was associated with more favorable glucose regulation, while Flavonifractor showed the opposite association. The study examined individual organisms, not whether increasing a total production-capacity score improves health.

A human genetic analysis linked greater genetically predicted activity of one microbial butyrate-producing pathway with a stronger insulin response to an oral glucose challenge. This supports a possible causal connection, subject to the assumptions of the genetic analysis. It doesn't show that raising this stool result prevents diabetes.

A study comparing 106 people with ME/CFS and 91 controls found reduced butyrate-producing capacity using stool sequencing and targeted gene measurements. Lower Faecalibacterium prausnitzii abundance was associated with worse fatigue. These findings describe an association; they haven't established this result as a diagnostic test or shown that increasing it relieves fatigue.

Transplant Research

Some of the strongest prospective associations come from people receiving donor stem cell transplants. Donor immune cells can attack the recipient’s tissues after transplantation. This complication is called graft-versus-host disease.

A study of 266 transplant recipients associated lower abundance of predicted butyrate producers around disease onset with worse outcomes. It used bacterial profiling to estimate producer abundance. A separate study of 201 transplant recipients measured a specific butyrate-production gene and linked prolonged suppression with gastrointestinal graft-versus-host disease and transplant-related mortality.

These studies used related measures of microbial capacity, rather than validating this particular reported score. They also involved severe illness, intensive treatment and substantial antibiotic exposure. They don't establish that screening healthy people, or treating a low result, improves survival.

Cancer and Other Disease Associations

Studies of colorectal cancer have reported lower chemical concentrations of butyrate in stool. Parkinson’s disease research has also linked lower fecal concentrations with greater clinical severity. Both findings concern the molecule remaining in stool, a different measurement from microbial genetic capacity.

Research in fatty liver disease combines measurements of bacterial abundance, fecal fatty acids and circulating fatty acids, with inconsistent findings. These studies haven't established this production-capacity result as a way to diagnose or predict these conditions.

Why Higher Isn't Automatically Better

A higher estimate indicates more genetic potential represented in the sampled community. The health implications also depend on which organisms and pathways contribute, what they are fermenting and what is happening in the gut lining. No outcome study has established that maximizing this result is beneficial.

When Results Can Be Misleading

• Capacity versus activity: DNA identifies potential functions. It doesn't establish whether those genes are active or how much butyrate reaches your colon cells.
• Relative abundance: Community proportions can change because other organisms expand or contract. A lower relative estimate doesn't necessarily mean the same-sized loss in the absolute number of butyrate-producing bacteria.
• Different analytical methods: Shotgun sequencing, functions inferred from 16S bacterial profiling, targeted gene PCR and chemical fatty acid testing produce different measurements. Their results aren't interchangeable.
• Sample handling and analysis: Collection, preservation, DNA extraction, sequencing depth and the reference databases used to identify microbial functions can affect the estimate.
• Recent changes in the gut: Antibiotics, bowel preparation, illness and changes in bowel habits can alter the community represented in a sample. A result during one of these periods may differ from your usual pattern.
• Stool versus the gut lining: Stool samples represent microbes shed into stool. They don't directly measure organisms attached to the intestinal lining or the lining’s ability to absorb and use butyrate.

What a Change Can Mean

A change can show that the sampled microbial community has shifted. It doesn't by itself establish a change in symptoms, inflammation or disease risk. Even a persistent change needs to be interpreted alongside what happened to your diet, medication use and health.